Search

Cytokinetics Inc

Cerrado

SectorSanidad

68.48 -1.71

Resumen

Variación precio

24h

Actual

Mínimo

68.42

Máximo

69.59

Métricas clave

By Trading Economics

Ingresos

7.3M

-199M

Ventas

13M

32M

BPA

-1.5

Margen de beneficios

-622.805

Empleados

673

EBITDA

-22M

-192M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+61.93% upside

Dividendos

By Acuity

Próximas Ganancias

4 nov 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-307M

10B

Apertura anterior

70.19

Cierre anterior

68.48

Noticias sobre sentimiento de mercado

By Acuity

33%

67%

54 / 339 Clasificación en Healthcare

Cytokinetics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

19 sept 2026, 00:02 UTC

Cytokinetics Inc is rising in after-market trading, gaining ground since Friday's close while positioned below its 20-day moving average.

18 sept 2026, 20:06 UTC

News

Cytokinetics Inc shares fell sharply, reaching their lowest point just before noon and finishing near the lower end of their one-month range.

17 sept 2026, 19:36 UTC

Cytokinetics Inc is trading slightly higher, having reached a session high earlier before pulling back, while remaining below its 20-day moving average.

16 sept 2026, 23:16 UTC

Cytokinetics Inc is experiencing a modest decline in after-market trading, reversing from an initial uptick and reaching its lowest point of the day.

15 sept 2026, 20:01 UTC

Cytokinetics Inc shares are lower as the NY Empire State Manufacturing Index fell sharply, raising concerns about economic contraction in the manufacturing sector.

11 sept 2026, 20:08 UTC

News
Social Media

Cytokinetics Inc shares are higher as analysts express positive sentiments, with Cantor Fitzgerald reiterating an Overweight rating and a price target of $112 from Truist.

9 sept 2026, 19:36 UTC

Cytokinetics Inc shares are lower today amid rising crude oil prices and inflation concerns. The stock is currently below its 20-day moving average.

8 sept 2026, 23:56 UTC

Cytokinetics Inc shares are higher in after-market trading, reflecting broader market sentiment following a strong jobs report and rising interest rate expectations.

4 sept 2026, 23:51 UTC

Cytokinetics Inc shares are higher in after-market trading, reaching their highest cumulative return of the day, despite no specific news driving the move.

3 sept 2026, 19:26 UTC

News

Cytokinetics Inc is trading higher as it announces participation in investor conferences and highlights an upcoming Supplemental New Drug Application for aficamten.

2 sept 2026, 23:16 UTC

News
Correlated Moves

Cytokinetics Inc shares are trading lower after-market following its investor conference announcements, with Ionis Pharmaceuticals' decline possibly impacting sentiment in the sector.

1 sept 2026, 20:09 UTC

News
Social Media

Cytokinetics Inc shares are higher as Truist and H.C. Wainwright reaffirm Buy ratings, citing positive momentum and potential from recent ESC conference insights.

31 ago 2026, 23:01 UTC

Cytokinetics Inc shares are lower in after-market trading amid broader market declines. Concerns over potential interest rate hikes may be influencing the downward trend.

28 ago 2026, 22:01 UTC

Event

Cytokinetics Inc shares are higher after announcing positive Phase 3 trial results for aficamten at the European Society of Cardiology Congress.

26 ago 2026, 20:08 UTC

Social Media

Cytokinetics shares advance amid social media discussions of a $100 price target, reflecting gains since Tuesday's close despite mixed U.S. market performance.

14 ago 2026, 19:26 UTC

Social Media

Cytokinetics shares are higher as H.C. Wainwright maintains a Buy rating and Barclays raises its price target to $110 amid strong sales momentum.

13 ago 2026, 23:21 UTC

Cytokinetics Inc shares are higher in after-market trading, recovering from three consecutive lower sessions, though still below the 20-day moving average.

12 ago 2026, 19:46 UTC

Cytokinetics Inc shares are lower today, continuing a decline since Tuesday's close. No specific news was identified to explain the movement.

11 ago 2026, 19:11 UTC

News

Cytokinetics Inc shares declined as CEO Robert I. Blum sold 7,500 shares at $76.76, raising investor concerns about executive confidence in the company.

10 ago 2026, 19:46 UTC

News
Social Media

Cytokinetics shares rise as Truist upgrades rating and raises price target to $112, while Citizens increases its target to $110 following strong Q2 results.

8 ago 2026, 00:01 UTC

Cytokinetics Inc shares are higher in after-market trading, recovering from earlier declines. The stock remains below its 20-day moving average.

7 ago 2026, 22:51 UTC

Cytokinetics shares are rising in after-market trading, recovering from earlier session lows amid positive sentiment in US equities and mixed labor data.

6 ago 2026, 23:21 UTC

News
Social Media

Cytokinetics reports Q2 2026 net loss of $198.8 million, better than expected. Shares are higher in after-market trading amid positive sentiment.

5 ago 2026, 20:06 UTC

Cytokinetics Inc shares are higher amid positive market sentiment and easing crude oil prices, despite a shift from recent daily closing trends.

4 ago 2026, 23:01 UTC

Cytokinetics Inc is higher in after-market trading, gaining since Tuesday's close, though still below its 20-day moving average with no specific news identified.

3 ago 2026, 19:36 UTC

Cytokinetics Inc shares are lower amid broader market trends influenced by geopolitical developments. Earlier in the session, shares pulled back from a session high.

31 jul 2026, 20:02 UTC

Event

Cytokinetics Inc is lower today amid a broader decline in the Biotechnology sub-sector, reversing a trend of higher daily closes since Thursday.

30 jul 2026, 18:46 UTC

Event
News
Social Media

Cytokinetics receives UK marketing authorization for MYQORZO, a treatment for obstructive hypertrophic cardiomyopathy. Shares are trading higher amid positive market sentiment.

29 jul 2026, 20:41 UTC

Cytokinetics Inc shares are lower in after-market hours, influenced by a broader market decline amid rising crude oil prices and anticipation of the Fed's policy announcement.

28 jul 2026, 19:06 UTC

News

Cytokinetics shares are lower amid investor concerns over CEO Robert I. Blum's recent stock option exercise and sale, reported earlier today.

Comparación entre iguales

Cambio de precio

Cytokinetics Inc previsión

Precio Objetivo

By TipRanks

61.93% repunte

Estimación a 12 Meses

Media 111.375 USD  61.93%

Máximo 146 USD

Mínimo 85 USD

De acuerdo con 17 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Cytokinetics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

17 ratings

16

Comprar

1

Mantener

0

Vender

Sentimiento

By Acuity

54 / 339 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Cytokinetics Inc

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. It develops small molecule drug candidates primarily engineered to impact muscle function and contractility. The company's drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. The company has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.